You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: interferon and nucleoside/tide analogues reduce risk of hepato-cellular cancer in chronic hepatitis B

https://doi.org/10.1136/ebm.14.3.86

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    QUESTION

    Do interferon and nucleoside/tide analogues reduce risk of hepatocellular cancer (HCC) in patients with chronic hepatitis B virus (HBV) infection?

    REVIEW SCOPE

    Included studies compared interferon, pegylated interferon, or nucleoside/tide analogues (lamivudine, adefovir, entecavir, and telbuvidine) with no antiviral treatment (in any study type) or placebo (in randomised controlled trials [RCTs]) in patients with confirmed chronic HBV infection. Outcome was chronic hepatitis B-related HCC.

    REVIEW METHODS

    Medline, EMBASE/Excerpta Medica, Cochrane Central Register of Controlled Trials and Database of Abstracts of Reviews of Effects, and International Pharmaceutical Abstracts (all to Nov or Dec 2007); abstracts from major international conferences in the past 10 years; and reference lists were searched for English-language RCTs, case–control studies, or cohort studies. 12 studies (n = 2742) …

    View Full Text

    Footnotes

    • Source of funding: not stated.